A considerable number of people with Parkinson’s disease living at home missed every flu vaccination given over five years despite being at higher risk of preventable respiratory infections, a single-site U.S. study of homebound and ambulatory patients found. Nearly 25% of these patients also expressed hesitancy about vaccines, and…
A mutant form of the alpha-synuclein protein — associated with early onset, severe familial Parkinson’s disease — recruits its normal version to propagate the toxic clumps that lead to neurodegeneration, a study in mice has found. The data, specific for the E46K mutant version of alpha-synuclein, suggest that…
Despite economic challenges due to COVID-19 shutdowns, the Parkinson’s Foundation is investing $10 million toward research, its care network, and community grants, the CEO of the nonprofit has announced. “As it turns out, our donors have really stayed with us,” said John L.
A new formulation of rasagiline, approved for Parkinson’s disease, may allow the therapy to be given by applying it to the skin. The treatment’s new formulation was described in the European Journal of Pharmaceutics and Biopharmaceutics, in a study titled “Microemulsion-based gel for the…
A four-ingredient, small-molecule cocktail was seen to protect stem cells from the stresses of lab work better than existing agents, helping to preserve their normal structure and function, researchers reported. This cocktail may overcome the “daunting challenge” of keeping pluripotent stem cells viable, so to be more useful in research into stem…
People with moderate or advanced Parkinson’s disease have abnormally low levels of caffeine in their saliva, despite normal caffeine metabolism, a new study indicates. The findings suggest that measuring caffeine in saliva could be useful for gauging Parkinson’s disease progression. The study, “Salivary caffeine in Parkinson’s…
Gain Therapeutics‘ investigational compounds were able to lessen motor symptoms in a rat model of GBA1-associated Parkinson’s disease and also decrease the levels of alpha-synuclein accumulation in nerve cells — two hallmarks of the neurodegenerative disease. The two candidates — GT-02287 and GT-02329 — are…
Alligator Bioscience and BioArctic AB have partnered to research and develop new therapies for neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully used to generate Alligator’s…
Parkinson’s disease does not appear to make a person more susceptible to infection with the COVID-19-causing virus, or at risk of poorer outcomes, according to a study in a small hospitalized patient group in Italy when the pandemic struck. The observational study, “The impact of SARS-COV2 infection on…
Centogene announced plans to recruit 2,500 more patients this year into its observational Rostock International Parkinson’s Disease (ROPAD) study of how genetic factors contribute to the development of Parkinson’s. “We recently reached a significant study milestone, but this is just the beginning,” Peter Bauer, MD, Centogene’s chief genomic…
Get regular updates to your inbox.